UNSPSC 51182041: Oxandrolone

This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C19H30O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7H6TM3CT4L, chemically known as 2-oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)- (9ci) but generally known as oxandrolone, which bears US NIH Compound Identifier 5878. European Medicines Agency schedules Oxandrolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09496MIG.

UNSPSC 51182041 Oxandrolone is a Commodity code representing pharmaceutical products — specifically generic anabolic steroids and controlled pharmaceuticals — that state and local government health systems, correctional facilities, and public hospitals procure through cooperative purchasing agreements and direct-award contracts. State and local governments source oxandrolone and similar controlled pharmaceuticals almost exclusively through multistate cooperative purchasing vehicles rather than individual jurisdiction RFPs, consolidating demand across dozens of participating states and local health authorities to negotiate volume-based pricing with manufacturers and wholesaler networks. Issuing bodies include state departments of health and administration, state procurement offices administering cooperative purchasing alliances, county health systems, and public hospital networks. The cooperative structure allows participating jurisdictions to leverage collective purchasing power while maintaining compliance with DEA scheduling, state pharmacy board regulations, and federal pharmaceutical supply chain security requirements.

The most recent documented activity is the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802, posted January 20, 2026 with a proposal due date of March 26, 2026, which establishes multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across Minnesota, Oregon, and other participating MMCAP member states and localities. The solicitation requires vendors to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health 110 and 112, and Morris & Dickson), provide detailed product information with National Drug Codes and manufacturing locations, maintain current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act compliance, hold $5 million commercial general liability and $2 million network security/professional liability insurance, and accept a 3 percent administrative fee structure with performance penalties of $200 to $1,500 per violation. Contract awards become effective July 1, 2026, with a two-year initial term and optional extensions at MMCAP's discretion.